Advertisement

Long non-coding RNA CDKN2B-AS1 promotes osteosarcoma by increasing the expression of MAP3K3 via sponging miR-4458

  • Daokun Gui
  • Hanqi CaoEmail author
Article
  • 1 Downloads

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor worldwide. Recently, several studies have shown that the long non-coding RNA (lncRNA) CDKN2B-AS1 plays a critical role in several cancers. However, the function and underlying mechanism of CDKN2B-AS1 in OS development remains elusive. In this study, we firstly assessed the expression of CDKN2B-AS1 in OS tissues and cells, showing that CDKN2B-AS1 expression were remarkably upregulated in OS tissues and cells. Moreover, CDKN2B-AS1 knockdown suppressed cell proliferation, migration, and EMT progress in OS. Interestingly, we found and proved that CDKN2B-AS1 could sponge miR-4458 in OS cells. Moreover, MAP3K3 was certified as a downstream target of miR-4458 in OS. Besides, MAP3K3 was negatively regulated by miR-4458 and positively regulated by CDKN2B-AS1. More importantly, overexpression of MAP3K3 could partly counteract the effect of CDKN2B-AS1 suppression on the biological behavior of OS cells. Also, the in vivo experiments further testified that CDKN2B-AS1 accelerated tumor growth in OS. Our results suggested that CDKN2B-AS1 facilitated OS progression by sponging miR-4458 to enhance MAP3K3 expression, which provides a novel insight into improving diagnostic and therapeutic strategies for patients with OS.

Keywords

CDKN2B-AS1 miR-4458 MAP3K3 Osteosarcoma 

Notes

Acknowledgments

We sincerely appreciate lab members for their support to our research.

Funding information

This research was supported by grants from Jiangsu Natural Science Foundation (BK20171265) and the Huai’an Key laboratory funded projects (HAP201608).

Compliance with ethical standards

Conflict of interest

The authors declare that there are no competing interests.

Supplementary material

11626_2019_415_Fig6_ESM.png (185 kb)
Supplementary Fig. 1

Quantitative figures of western blot assay in the study. (A) Quantitative figure of western blot assay in Fig. 1H. (B) Quantitative figure of western blot assay in Fig. 3D. (C) Quantitative figure of western blot assay in Fig. 4F. *P < 0.05. (PNG 185 kb)

11626_2019_415_MOESM1_ESM.tif (9.7 mb)
High resolution image (TIF 9891 kb)
11626_2019_415_Fig7_ESM.png (191 kb)
Supplementary Fig. 2

The location of target sites between miR-4458 and CDKN2B-AS1/ MAP3K3. (A-B) the location of putative binding sites for miR4458 in full length of CDKN2B-AS1 or 3’UTR of MAP3K3 was displayed. (PNG 190 kb)

11626_2019_415_MOESM2_ESM.tif (4.8 mb)
High resolution image (TIF 4966 kb)

References

  1. Akhade VS, Pal D, Kanduri C (2017) Long noncoding RNA: genome organization and mechanism of action. Adv Exp Med Biol 1008:47–74CrossRefGoogle Scholar
  2. An Q, Zhou L, Xu N (2018) Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. Biomed Pharmacother 103:415–420CrossRefGoogle Scholar
  3. Burdon KP, Macgregor S, Hewitt AW, Sharma S, Chidlow G, Mills RA, Danoy P, Casson R, Viswanathan AC, Liu JZ, Landers J, Henders AK, Wood J, Souzeau E, Crawford A, Leo P, Wang JJ, Rochtchina E, Nyholt DR, Martin NG, Montgomery GW, Mitchell P, Brown MA, Mackey DA, Craig JE (2011) Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. Nat Genet 43:574–578CrossRefGoogle Scholar
  4. Chen X, Chen Z, Yu S, Nie F, Yan S, Ma P, Chen Q, Wei C, Fu H, Xu T, Ren S, Sun M, Wang Z (2018) Long noncoding RNA LINC01234 functions as a competing endogenous RNA to regulate CBFB expression by sponging miR-204-5p in gastric Cancer. Clin Cancer Res 24:2002–2014CrossRefGoogle Scholar
  5. Dong J, Su M, Chang W, Zhang K, Wu S, Xu T (2017) Long non-coding RNAs on the stage of cervical cancer (review). Oncol Rep 38:1923–1931CrossRefGoogle Scholar
  6. Fei D, Zhang X, Liu J, Tan L, Xing J, Zhao D, Zhang Y (2018) Long noncoding RNA FER1L4 suppresses tumorigenesis by regulating the expression of PTEN targeting miR-18a-5p in osteosarcoma. Cell Physiol Biochem 51:1364–1375CrossRefGoogle Scholar
  7. Hu XH, Dai J, Shang HL, Zhao ZX, Hao YD (2018) High levels of long non-coding RNA DICER1-AS1 are associated with poor clinical prognosis in patients with osteosarcoma. Eur Rev Med Pharmacol Sci 22:7640–7645PubMedGoogle Scholar
  8. Huang Y, Xiang B, Liu Y, Wang Y, Kan H (2018) LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis. Cancer Lett 437:56–66CrossRefGoogle Scholar
  9. Isakoff MS, Bielack SS, Meltzer P, Gorlick R (2015) Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol 33:3029–3035CrossRefGoogle Scholar
  10. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefGoogle Scholar
  11. Jin M, Zhang T, Liu C, Badeaux MA, Liu B, Liu R, Jeter C, Chen X, Vlassov AV, Tang DG (2014) miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells. Cancer Res 74:4183–4195CrossRefGoogle Scholar
  12. Li H, Han S, Sun Q, Yao Y, Li S, Yuan C, Zhang B, Jing B, Wu J, Song Y, Wang H (2019) Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression. Aging (Albany NY) 11:1695–1715CrossRefGoogle Scholar
  13. Lian Y, Xiong F, Yang L, Bo H, Gong Z, Wang Y, Wei F, Tang Y, Li X, Liao Q, Wang H, Zhou M, Xiang B, Wu X, Li Y, Li X, Chen X, Li G, Guo C, Zeng Z, Xiong W (2018) Long noncoding RNA AFAP1-AS1 acts AS a competing endogenous RNA of miR-423-5p to facilitate nasopharyngeal carcinoma metastasis through regulating the Rho/Rac pathway. J Exp Clin Cancer Res 37:253CrossRefGoogle Scholar
  14. Liu CH, Lv DS, Li M, Sun G, Zhang XF, Bai Y (2017) MicroRNA-4458 suppresses the proliferation of human lung cancer cells in vitro by directly targeting Lin28B. Acta Pharmacol Sin 38:1297–1304CrossRefGoogle Scholar
  15. Lu G, Li Y, Ma Y, Lu J, Chen Y, Jiang Q, Qin Q, Zhao L, Huang Q, Luo Z, Huang S, Wei Z (2018) Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/E2F1/Nanog axis. J Exp Clin Cancer Res 37:289CrossRefGoogle Scholar
  16. Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: insights into functions. Nat Rev Genet 10:155–159CrossRefGoogle Scholar
  17. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's oncology group. J Clin Oncol 26:633–638CrossRefGoogle Scholar
  18. Miller BJ, Gao Y, Duchman KR (2017) Socioeconomic measures influence survival in osteosarcoma: an analysis of the National Cancer Data Base. Cancer Epidemiol 49:112–117CrossRefGoogle Scholar
  19. Pan R, He Z, Ruan W, Li S, Chen H, Chen Z, Liu F, Tian X, Nie Y (2018) lncRNA FBXL19-AS1 regulates osteosarcoma cell proliferation, migration and invasion by sponging miR-346. Onco Targets Ther 11:8409–8420CrossRefGoogle Scholar
  20. Sun Y, Wang P, Yang W, Shan Y, Zhang Q, Wu H (2019) The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and gemcitabine-induced apoptosis. Cancer Biol Ther.  https://doi.org/10.1080/15384047.2018.1529121:1-11
  21. Tang D, Sun B, Yu H, Yang Z, Zhu L (2015) Tumor-suppressing effect of miR-4458 on human hepatocellular carcinoma. Cell Physiol Biochem 35:1797–1807CrossRefGoogle Scholar
  22. Tang H, Lv W, Sun W, Bi Q, Hao Y (2019) miR505 inhibits cell growth and EMT by targeting MAP3K3 through the AKTNF kappaB pathway in NSCLC cells. Int J Mol Med 43:1203–1216PubMedGoogle Scholar
  23. Wang R, Sun Y, Yu W, Yan Y, Qiao M, Jiang R, Guan W, Wang L (2019c) Downregulation of miRNA-214 in cancer-associated fibroblasts contributes to migration and invasion of gastric cancer cells through targeting FGF9 and inducing EMT. J Exp Clin Cancer Res 38:20CrossRefGoogle Scholar
  24. Wang X, Kan J, Han J, Zhang W, Bai L, Wu H (2019b) LncRNA SNHG16 functions as an oncogene by sponging MiR-135a and promotes JAK2/STAT3 signal pathway in gastric cancer. J Cancer 10:1013–1022CrossRefGoogle Scholar
  25. Wang Y, Chen F, Zhao M, Yang Z, Li J, Zhang S, Zhang W, Ye L, Zhang X (2017) The long noncoding RNA HULC promotes liver cancer by increasing the expression of the HMGA2 oncogene via sequestration of the microRNA-186. J Biol Chem 292:15395–15407CrossRefGoogle Scholar
  26. Wang Y, Huang Y, Liu H, Su D, Luo F, Zhou F (2019a) Long noncoding RNA CDKN2B-AS1 interacts with miR-411-3p to regulate ovarian cancer in vitro and in vivo through HIF-1a/VEGF/P38 pathway. Biochem Biophys Res Commun 514:44–50CrossRefGoogle Scholar
  27. Xia F, Chen Y, Jiang B, Du X, Peng Y, Wang W, Huang W, Feng T, Li X (2018) Long noncoding RNA HOXA-AS2 promotes papillary thyroid cancer progression by regulating miR-520c-3p/S100A4 pathway. Cell Physiol Biochem 50:1659–1672CrossRefGoogle Scholar
  28. Xie CR, Wang F, Zhang S, Wang FQ, Zheng S, Li Z, Lv J, Qi HQ, Fang QL, Wang XM, Yin ZY (2017) Long noncoding RNA HCAL facilitates the growth and metastasis of hepatocellular carcinoma by acting as a ceRNA of LAPTM4B. Mol Ther Nucleic Acids 9:440–451CrossRefGoogle Scholar
  29. Zhao L, Ni X, Zhao L, Zhang Y, Jin D, Yin W, Wang D, Zhang W (2018) MiroRNA-188 acts as tumor suppressor in non-small-cell lung cancer by targeting MAP3K3. Mol Pharm 15:1682–1689CrossRefGoogle Scholar
  30. Zhu L, Zhang Q, Li S, Jiang S, Cui J, Dang G (2019) Interference of the long noncoding RNA CDKN2B-AS1 upregulates miR-181a-5p/TGFbetaI axis to restrain the metastasis and promote apoptosis and senescence of cervical cancer cells. Cancer Med.  https://doi.org/10.1002/cam4.2040 CrossRefGoogle Scholar

Copyright information

© The Society for In Vitro Biology 2020

Authors and Affiliations

  1. 1.Department of OrthopaedicsLianshui County People’s HospitalJiangsu ProvinceChina
  2. 2.Department of OrthopaedicsThe Affiliated Huai’an Hospital of Xuzhou Medical University and The Second People’s Hospital of Huai’anJiangsu ProvinceChina

Personalised recommendations